Lv51
1270 积分 2024-01-11 加入
Origins and consequences of cognitive fatigue
3天前
已完结
Why time poverty matters for individuals, organisations and nations
3天前
已完结
The next generation of immunotherapies for lung cancers
7天前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
7天前
已完结
When the real world becomes the trial
7天前
已完结
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
16天前
已完结
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer
16天前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
16天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
28天前
已完结
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)
29天前
已完结
皖公网安备34019202002308
